COMPLEMENT ACTIVITY MODULATORS Russian patent published in 2022 - IPC A61K38/12 A61K39/395 A61K47/02 A61K9/00 A61P7/00 A61P13/02 A61P43/00 G01N33/68 

FIELD: pharmaceutics.

SUBSTANCE: group of inventions relates to polypeptide modulators of complement activity, including cyclic polypeptide modulators. A method of treating a complement-related disorder in a subject who has not previously received eculizumab treatment includes: introduction of a polypeptide inhibiting C5, having a core sequence SEQ ID NO: 1, to a subject in an initial loading dose of 0.1 to 0.6 mg/kg; and administering a C5 inhibiting polypeptide having the core sequence SEQ ID NO: 1, to a subject in an initial therapeutic dose of 0.1 to 0.3 mg/kg, wherein the initial therapeutic dose is administered at least twice at regular intervals after the initial loading dose, wherein lactate dehydrogenase (LDH) levels in the subject are monitored during therapy, and wherein the initial therapeutic dose is replaced with a modified therapeutic dose of 0.3 to 0.6 mg/kg after at least two weeks of administering the initial therapeutic dose or when the LDH levels in the subject do not exceed 1.5 times the normal upper limit. Also disclosed is a version of a method of treating a complement-related disorder in a subject for another group of patients.

EFFECT: group of inventions provides selective blocking of complement-mediated cell destruction.

19 cl, 34 dwg, 11 tbl, 23 ex